Annotated highest absolute variance abstracts

15298734

Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer.
Ikuo Sekine, Kazumasa Noda, Fumihiro Oshita, Kouzou Yamada, Manabu Tanaka, Kosuke Yamashita, Hiroshi Nokihara, Noboru Yamamoto, Hideo Kunitoh, Yuichiro Ohe, Tomohide Tamura, Tetsuro Kodama, Minako Sum ...
(Division of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan. isekine@ncc.go.jp)
Cancer Sci.

cisplatin single cycles days conclusion toxicity rest cancer rates time grade_3-4 for weeks ten was in iii the vinorelbine_mg/m2 at 3-year_survival thoracic_radiotherapy were recommended_dose lung confidence_interval months recommended_phase regimen promising or with and dose nsclc patients of level same total fifteen response_rate then mg/m2 1-year_2-year chemotherapy received overall partial_responses trt feasible unresectable_stage vinorelbine gy developed on_day cisplatin_mg/m2 followed_by all stage_iii infection median_survival every_weeks noted is combination ii on once_daily dose-limiting_toxicity non-small_cell grade_esophagitis respectively determine none this 59-96 to consisted four

12239453

Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer (stage IIIb or IV) with a higher T stage (> T2). Technetium-99m methoxyisobutylisonitrile chest single photon emission computed tomography and P-glycoprotein express ion.
Wu-Huei Hsu, Ruoh-Fang Yen, Chia-Hung Kao, Shih-Chih Shiun, Nan-Yung Hsu, Cheng-Chieh Lin, Cheng-Chun Lee
(Division of Pulmonary/Critical Care Medicine, Department of Medicine, China Medical College Hospital, Taichung, Taiwan.)
Oncology

t/nl sections tc-mibi difference understand biopsy_specimens ten were prognostic_factors tc-mibi_chest p-glycoprotein_pgp found after early immunohistochemical_analyses paclitaxel multiple_nonconsecutive tumor compare qualitatively after_completion calculated performance_status with quantitatively third_month loss negative can_be could_be stage determine no_significant treatment positive technetium-99m_methoxyisobutylisonitrile detected iv used predict however was in expression student_test poor lung performed evaluated single_photon patients and interpreted of quickly cases chemotherapy radiological +/ spect_images spect enrolled significant body_weight on differences other clinical intravenous_injection age_sex cancer min tomography_spect for emission_computed before chest the these tumor-to-normal an_independent good nsclc pgp this_study aim response between by all stage_iiib groups results type cell to methods or

12966417

Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer.
A Fujita, T Ohkubo, H Hoshino, H Takabatake, S Tagaki, K Sekine, S Abe
(Division of Respiratory Disease, Minami-ichijo Hospital, South-1 West-13, Chuo-ku, Sapporo 060-0061, Japan. afujita@sa2.so-net.ne.jp)
Br. J. Cancer

cisplatin august conclusion previously_untreated days toxicity assessable cancer microg rates survival recombinant_human iv mg time for weeks given was in granulocyte_colony were at the regimen 2-year_survival confidence_interval days_5-18 rhg-csf duration with and patients of nsclc registered dose total grade achieved except acceptable_toxicities highly_effective response administered_subcutaneously median days_1-4 4-77 progression developed irinotecan all stage_iiib median_survival stimulating_factor study thrombocytopenia an phase_ii ifosfamide combination administered on conducted this rhg-csf_support respectively repeated_every objective_response between_june to or treatment

12411157

Significance and expression of vascular endothelial growth factor and E-cadherin in non-small cell lung Carcinomas.
Tonghua Mei, Liping Zhang, Ying Ma
(Department of Lung, Second Affiliated Hospital, Chongqing University of Medical Sciences, Chongqing 400010, China.)
Zhonghua Yu Fang Yi Xue Za Zhi

poor-middle-differentiation metastasis rates good-differentiation from e-cd immunohistochemical vascular_endothelial was in the were without expression that lung invasion well case sp with and nsclc of carcinomas analyzed cases e-cadherin by different growth_factor explore significantly study mechanism cell is those correlated method vegf surgical_specimens non-small_cell tumor

15886471

A phase II study of docetaxel and infusional cisplatin in advanced non-small-cell lung cancer.
Kiyoshi Mori, Yukari Kamiyama, Tetsuro Kondo, Yasuhiko Kano, Tetsuro Kodama
(Department of Thoracic Diseases, Tochigi Cancer Center, Yonan, Utsunomiya, Japan. kmori@tcc.pref.tochigi.jp)
Chemotherapy

cisplatin pid previously_untreated days cycles 1-year_survival 5-day_continuous toxicity cancer patient grade 9-63 time infusion therapy for weeks was rate at the were docetaxel mean number well-tolerated regimen lung confidence_interval efficacy toxic_effects status patients and with nsclc of cisplatin_mg/m2/day mg/m2/day interval response_rate major safety anemia neutropenia_leukopenia chemotherapy ecog_performance 4-week received advanced_non-small-cell continuous_infusion eligible enrolled active there median_survival bolus 0-2 an ranged_from thrombocytopenia per no_treatment-related combination on measurable administered advanced_nsclc deaths to forty-three or treatment evaluate

16865253

Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy.
Katsuhiko Endo, Hidefumi Sasaki, Motoki Yano, Yoshihiro Kobayashi, Haruhiro Yukiue, Hiroshi Haneda, Eriko Suzuki, Osamu Kawano, Yoshitaka Fujii
(Department of Surgery II, Nagoya City University Medical School, Nagoya 467-8601, Japan.)
Oncol. Rep.

gefitinib longer conclusion cancer gefitinib-treated relation survival gene increased predictor suggested_that higher pathological presence predictors japanese better but_not we was in the associated number erbb2 lung some clinical_outcome patients and with of nsclc studies analyzed cases their response_rate overall_survival significantly_correlated egfr but epidermal_growth factor_receptor mutation gene_amplification than gefitinib-naïve subtypes may_be have gene_copy not smoking_status egfr_mutation studied also several other non-small_cell gender biomarkers copy_number sensitivity to

23736019

A meta-analysis of the association between glutathione S-transferase P1 gene polymorphism and the risk of adenocarcinomas of lung cancer.
Hong Zhong, Yi Feng, Gui-Xiong Zheng, Yan Liang, Jun-Yuan Zhang, Bao-Shi Zheng, Xu Feng
(Department of Cardio-Thoracic Surgery, People's Hospital of Beihai, Beihai, China.)
Cancer Biomark

pubmed p1_gstp1 cancer risk synthesized non-sensitivity gene from adenocarcinomas for was glutathione_s-transferase polymorphism in the were associated lung performed gg_genotype with and of biomarker identified studies included are cochrane_library association_between into be gstp1_a/g eligible susceptibility still_debated gstp1 meta-analysis results reports using not is those association method analysis on published_reports this investigations allele furthermore similar to sensitivity or

21925717

Prognostic significance of RIN1 gene expression in human non-small cell lung cancer.
Qun Wang, Ying Gao, Yufu Tang, Lie Ma, Mingjing Zhao, Xiaoge Wang
(Department of Respiratory Medicine, The Fourth Affiliated Hospital of China Medical University, Shenyang, People's Republic of China.)
Acta Histochem.

metastasis showed tissues role may_offer detect cancer its levels multivariate_analysis human observed corresponding_non-tumor than_those for implicated lymph_node we was over-expression in rate the were interaction/interference expression prognosis rt-pcr that ras lung performed high-level poor an_independent with and patients of nsclc found as analyze cases lower overall_survival cancers significantly_higher tnm_stage this_study tumorigenesis our rin1 aim suggests_that progression differentiation high examine has_been study predicting originally_identified correlated protein development association mrna tissue_samples prognostic_factor may_play non-small_cell tumor an_important ras_effector outcome valuable immunohistochemistry to marker

23264086

High expression of FOXC1 is associated with poor clinical outcome in non-small cell lung cancer patients.
Long-Xiao Wei, Run-Suo Zhou, Hai-Feng Xu, Jun-Yan Wang, Meng-Hui Yuan
(Department of Nuclear Medicine, Tangdu Hospital, Fourth Military Medical University, No. 1, Xinsi Rd, Xi'an, 710038, China.)
Tumour Biol.

metastasis showed tissues role may_offer detect cancer its levels multivariate_analysis human corresponding_non-tumor than_those for lymph_node over-expression we was outcome in rate the were prognosis expression that lower high-level lung performed poor an_independent with and patients nsclc of foxc1 found analyze cases overall_survival tumor-node-metastasis_stage our significantly_higher this_study aim by suggests_that progression differentiation high predicting study correlated association mrna expressional protein tissue_samples western_blotting pcr non-small_cell examined tumor prognostic_factor may_play an_important valuable immunohistochemistry to marker low

23229099

Overexpression of MAC30 is associated with poor clinical outcome in human non-small-cell lung cancer.
Kai-Yu Han, Xin Gu, Hao-Ran Wang, Dong Liu, Fu-Zhen Lv, Jia-Ning Li
(Department of Respiratory Medicine, The Second Affiliated Hospital of Harbin Medical University, No. 148, Baojian Rd, Nangang District, Harbin, 150086, Heilongjiang Province, China.)
Tumour Biol.

metastasis showed tissues role may_offer detect cancer its levels multivariate_analysis human corresponding_non-tumor than_those for lymph_node over-expression we was outcome in rate the were prognosis expression rt-pcr that high-level lung performed poor an_independent with and patients nsclc of mac30 found analyze cases lower overall_survival our significantly_higher tnm_stage this_study aim suggests_that progression differentiation high examine predicting study correlated association mrna tissue_samples protein prognostic_factor may_play non-small_cell tumor an_important valuable immunohistochemistry to marker low